Send to

Choose Destination
Int J Clin Exp Med. 2014 May 15;7(5):1289-96. eCollection 2014.

Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.

Author information

Department of Rheumatology and Immunology, West China Hospital of Sichuan University Chengdu, China.
Department of Pulmonary Diseases, State Key Laboratory of Biotherapy of China and Department of Respiratory Medicine, West China Hospital of Sichuan University Chengdu, China.
West China School of Medicine, Sichuan University Chengdu, China.


It is reported that osteopontin has shown promising diagnostic value for malignant pleural mesothelioma (MPM), this meta-analysis aimed to establish the overall diagnostic accuracy of the osteopontin measurement for diagnosing MPM. Based on a systematic review of English language studies, the sensitivity, specificity and other measures of accuracy of osteopontin in the diagnosis of MPM were pooled using random-effects model. Summary receiver operating characteristic curves were used to summarize overall test performance. Seven publications met our inclusion criteria, the pooled sensitivity was 0.57 (95%CI: 0.52-0.61), specificity was 0.81, 95%CI: 0.79-0.84). The PLR was 3.78 (95%CI: 2.23-6.41), the NLR was 0.51 (95%CI: 0.38-0.67) and the DOR was 9.04 (95%CI: 5.28-15.48), the area under the summary receiver operating characteristic curve was 0.80. Our data suggest that osteopontin is likely to be a useful diagnostic marker for MPM, considering for the limited studies and patients included, larger studies are needed to confirm these findings.


Osteopontin; malignant pleural mesothelioma; meta-analysis


Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center